The researchers found that 13.9 percent of 158,849 eligible patients with heart failure and an LVEF >40 percent were prescribed an SGLT2i at hospital discharge. There was an increase in quarterly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback